Display options
Cite
Petrelli F, Iaculli A, Signorelli D, et al. Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis. J Clin Med. 2020;9(5)doi: 10.3390/jcm9051458.
Petrelli, F., Iaculli, A., Signorelli, D., Ghidini, A., Dottorini, L., Perego, G., Ghidini, M., Zaniboni, A., Gori, S., & Inno, A. (2020). Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis. Journal of clinical medicine, 9(5), . https://doi.org/10.3390/jcm9051458
Petrelli, Fausto, et al. "Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis." Journal of clinical medicine vol. 9,5 (2020). doi: https://doi.org/10.3390/jcm9051458
Petrelli F, Iaculli A, Signorelli D, Ghidini A, Dottorini L, Perego G, Ghidini M, Zaniboni A, Gori S, Inno A. Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis. J Clin Med. 2020 May 13;9(5). doi: 10.3390/jcm9051458. PMID: 32414103; PMCID: PMC7290584.
Copy Download .nbib Format: NLM
Share it on

J Clin Med. 2020 May 13;9(5). doi: 10.3390/jcm9051458.

Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis.

Journal of clinical medicine

Fausto Petrelli, Alessandro Iaculli, Diego Signorelli, Antonio Ghidini, Lorenzo Dottorini, Gianluca Perego, Michele Ghidini, Alberto Zaniboni, Stefania Gori, Alessandro Inno

Affiliations

  1. Oncology Unit, ASST Bergamo Ovest, 24047 Treviglio, Italy.
  2. Oncology Unit, ASST Bergamo Est, 24068 Alzano Lombardo, Italy.
  3. Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori di Milano, 20133 Milano, Italy.
  4. Oncology Unit, Casa di cura Igea, 20129 Milano, Italy.
  5. Pharmacy Unit, IRCCS San Raffaele Hospital, 20132 Milano, Italy.
  6. Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milano, Italy.
  7. Oncology Unit, Fondazione Poliambulanza, 25124 Brescia, Italy.
  8. Oncology Unit, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, 37024 Verona, Italy.

PMID: 32414103 PMCID: PMC7290584 DOI: 10.3390/jcm9051458

Abstract

Antibiotics (ABs) are common medications used for treating infections. In cancer patients treated with immune checkpoint inhibitors (ICIs), concomitant exposure to ABs may impair the efficacy of ICIs and lead to a poorer outcome compared to AB non-users. We report here the results of a meta-analysis evaluating the effects of ABs on the outcome of patients with solid tumours treated with ICIs. PubMed, the Cochrane Library and Embase were searched from inception until September 2019 for observational or prospective studies reporting the prognoses of adult patients with cancer treated with ICIs and with or without ABs. Overall survival (OS) was the primary endpoint, and progression-free survival (PFS) was the secondary endpoint. The effect size was reported as hazard ratios (HRs) with a 95% confidence interval (CI) and an HR > 1 associated with a worse outcome in ABs users compared to AB non-users. Fifteen publications were retrieved for a total of 2363 patients. In the main analysis (

Keywords: antibiotic; cancer; immune checkpoint inhibitors; meta-analysis; survival

References

  1. J Immunother Cancer. 2019 Jul 10;7(1):176 - PubMed
  2. J Clin Med. 2019 Jul 10;8(7): - PubMed
  3. Oncoimmunology. 2019 Feb 18;8(4):e1568812 - PubMed
  4. Anticancer Res. 2019 Oct;39(10):5675-5682 - PubMed
  5. Ann Oncol. 2018 Dec 1;29(12):2396-2398 - PubMed
  6. Lung Cancer. 2019 Apr;130:10-17 - PubMed
  7. Oncoimmunology. 2019 Sep 23;8(12):e1665973 - PubMed
  8. Science. 2018 Jan 5;359(6371):104-108 - PubMed
  9. BMJ. 2009 Jul 21;339:b2535 - PubMed
  10. Lung Cancer. 2019 Jun;132:72-78 - PubMed
  11. Oncologist. 2020 Jan;25(1):55-63 - PubMed
  12. Oncol Lett. 2019 Mar;17(3):2946-2952 - PubMed
  13. J Immunother Cancer. 2019 Sep 5;7(1):242 - PubMed
  14. Oncotarget. 2018 Mar 27;9(23):16512-16520 - PubMed
  15. Ann Oncol. 2018 Jun 1;29(6):1437-1444 - PubMed
  16. JAMA Oncol. 2019 Sep 12;: - PubMed
  17. Science. 2018 Jan 5;359(6371):97-103 - PubMed
  18. Science. 2015 Nov 27;350(6264):1084-9 - PubMed
  19. Oncoimmunology. 2018 Aug 20;7(11):e1507670 - PubMed
  20. Science. 2015 Nov 27;350(6264):1079-84 - PubMed
  21. Science. 2018 Jan 5;359(6371):91-97 - PubMed
  22. Anticancer Res. 2017 Jun;37(6):3195-3200 - PubMed
  23. Science. 2018 Mar 23;359(6382):1350-1355 - PubMed
  24. BMJ. 2003 Sep 6;327(7414):557-60 - PubMed
  25. Crit Rev Oncol Hematol. 2019 Nov;143:139-147 - PubMed

Publication Types